Yes, memantine is commonly prescribed together with cholinesterase inhibitors such as donepezil to address different aspects of Alzheimer’s pathology. The combination should be coordinated by a healthcare professional who will monitor for additive side effects.
Report the symptom to your prescriber promptly. Hallucinations may indicate a need to adjust the dose, assess for drug interactions, or consider alternative therapy.
Both strengths have comparable bioavailability; the difference lies only in the amount of active ingredient per tablet.
Yes, but carry a copy of the prescription and the original packaging. Some countries require a doctor’s letter; verify requirements with the destination’s health authority.
Occasional reports of hypertension have been documented, but it is not a common effect. Routine blood pressure monitoring is advisable, especially in patients with pre-existing hypertension.
St. John’s wort induces certain liver enzymes that could modestly affect memantine levels, though the interaction is not considered clinically significant. Nonetheless, disclose all supplements to your prescriber.
Generic memantine contains the same active ingredient and is bioequivalent. Switching should be discussed with your prescriber to ensure continuity of care.
Clinical improvement may become apparent after 4-12 weeks of stable dosing, but individual response varies.
When taken as prescribed, most patients do not experience impairments that affect driving. However, if you feel dizzy or disoriented, avoid operating vehicles until the symptoms resolve.
Do not keep them for later use. Return unused tablets to a pharmacy disposal program or follow local NHS guidelines for safe disposal.
Namenda is a prescription medication marketed in the United Kingdom under the brand name Namenda. Its sole active ingredient is memantine, an NMDA-receptor antagonist that belongs to the neurology therapeutic class. Memantine is supplied as an oral pill in strengths of 5 mg and 10 mg. The drug is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of moderate to severe Alzheimer's disease in adults.
Memantine blocks the activity of N-methyl-D-aspartate (NMDA) receptors, which are part of the glutamate neurotransmission system. In Alzheimer’s disease, excessive glutamate can overstimulate NMDA receptors, leading to calcium overload and neuronal injury. By acting as an NMDA-receptor antagonist, memantine reduces this excitotoxic damage while preserving normal physiological signalling.
Key pharmacologic features
Namename (memantine) is formally approved by the MHRA for adults with moderate to severe Alzheimer's disease. It is indicated as a symptomatic treatment to improve cognition, function, and behaviour, but it does not cure the underlying neurodegeneration.
Typical patient profile
While the primary approval is for Alzheimer’s disease, some peer-reviewed studies have explored memantine for other neurological conditions. These uses are not approved by the MHRA and should only be considered under specialist supervision.
Disclaimer: Off-label use requires individualized risk assessment and close monitoring by a qualified healthcare professional.
Absolute contraindications
Known hypersensitivity to memantine or any tablet excipients.
Severe renal impairment (creatinine clearance < 30 mL/min) where the drug cannot be safely cleared.
Relative contraindications
Moderate renal dysfunction (creatinine clearance 30-60 mL/min); dose reduction may be necessary.
History of seizures; memantine may lower the seizure threshold.
These effects are usually transient and resolve with continued therapy or dose adjustment.
If any of these occur, seek urgent medical attention.
Note: All tablets are available in 5 mg and 10 mg strengths; the 20 mg total daily dose is reached by dosing twice daily with the 10 mg tablet.
This article provides educational information about Namenda (memantine) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
